We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

224 hedge funds and large institutions have $2.68B invested in Amicus Therapeutics in 2019 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 86 increasing their positions, 57 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 26

65% more call options, than puts

Call options by funds: $9.49M | Put options by funds: $5.74M

51% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 57

22% more capital invested

Capital invested by funds: $2.2B → $2.68B (+$482M)

9% more funds holding

Funds holding: 205224 (+19)

0.35% more ownership

Funds ownership: 107.63%107.98% (+0.35%)

14% less funds holding in top 10

Funds holding in top 10: 76 (-1)

Holders
224
Holders Change
+19
Holders Change %
+9.27%
% of All Funds
4.41%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.12%
New
50
Increased
86
Reduced
57
Closed
26
Calls
$9.49M
Puts
$5.74M
Net Calls
+$3.74M
Net Calls Change
-$1.35M
Name Holding Trade Value Shares
Change
Change in
Stake
SSA
126
Schonfeld Strategic Advisors
New York
$571K -$1.32M -144,574 -71%
JG
127
Jefferies Group
New York
$569K +$535K +58,400 New
SBH
128
Segall Bryant & Hamill
Illinois
$543K -$37.8K -4,133 -7%
AG
129
Aperio Group
California
$514K +$243K +26,596 +102%
Two Sigma Advisers
130
Two Sigma Advisers
New York
$500K +$470K +51,376 New
XK
131
Xact Kapitalforvaltning
Sweden
$480K
Tudor Investment Corp
132
Tudor Investment Corp
Connecticut
$479K +$173K +18,851 +62%
ECM
133
ExodusPoint Capital Management
New York
$452K +$217K +23,757 +105%
AB
134
Amalgamated Bank
New York
$443K +$40.7K +4,451 +11%
TC
135
TwinBeech Capital
New York
$420K +$395K +43,103 New
CIM
136
CIM Investment Management
Pennsylvania
$402K +$378K +41,242 New
Brown Advisory
137
Brown Advisory
Maryland
$374K +$351K +38,363 New
BNP Paribas Financial Markets
138
BNP Paribas Financial Markets
France
$370K -$67.3K -7,352 -16%
BC
139
Birchview Capital
Vermont
$370K
DCM
140
Dupont Capital Management
Delaware
$341K
Group One Trading
141
Group One Trading
Illinois
$293K +$203K +22,168 +280%
Public Employees Retirement Association of Colorado
142
Public Employees Retirement Association of Colorado
Colorado
$270K
DTL
143
Dynamic Technology Lab
Singapore
$260K -$85.9K -9,381 -26%
Wolverine Trading
144
Wolverine Trading
Illinois
$258K +$248K +27,040 New
HSBC Holdings
145
HSBC Holdings
United Kingdom
$247K -$195K -21,285 -46%
BBVA
146
Banco Bilbao Vizcaya Argentaria
Spain
$243K +$229K +25,000 New
PA
147
Profund Advisors
Maryland
$242K +$39.8K +4,352 +21%
ACM
148
AlphaCrest Capital Management
New York
$224K +$45.5K +4,973 +28%
AGM
149
Alpine Global Management
New York
$222K +$209K +22,782 New
CL
150
CSS LLC
Illinois
$221K -$68.7K -7,500 -25%

FOLD Hedge Fund Activity: Q4 2019 in Review

224 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2019, worth a combined $2.68B — up 22% from $2.2B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new FOLD positions and 26 closed out — a net gain of 24 holders — while 86 added to existing stakes and 57 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $27.4M. The largest seller was Deutsche Bank, cutting an estimated $36.7M.

  • 224 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2019, up from 205 in Q3 2019.
  • Funds reported $2.68B of Amicus Therapeutics stock for Q4 2019, up 22% quarter-over-quarter.
  • 50 funds opened new Amicus Therapeutics positions in Q4 2019 and 26 closed out, a net change of +24 holders.
  • The largest Amicus Therapeutics buyer in Q4 2019 was JP Morgan Chase, an estimated $27.4M added.
  • The largest Amicus Therapeutics seller in Q4 2019 was Deutsche Bank, an estimated $36.7M sold.

Based on aggregated 13F filings for Q4 2019.